Bristol-Myers Squibb (NYSE:BMY) Shares Unloaded Rep. Greg Landsman

Representative Greg Landsman (D-Ohio) recently sold shares of Bristol-Myers Squibb (NYSE:BMY). In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol-Myers Squibb stock on March 27th. The trade occurred in the Representative’s “ROCKEFELLER CAPITAL MANAGEMENT (2)” account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Cadence Design Systems (NASDAQ:CDNS) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Simon Property Group (NYSE:SPG) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of L3Harris Technologies (NYSE:LHX) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Visa (NYSE:V) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Cencora (NYSE:COR) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Ameriprise Financial (NYSE:AMP) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Equinix (NASDAQ:EQIX) on 3/27/2025.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $50.45 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a market cap of $102.66 billion, a PE ratio of -11.41, a PEG ratio of 2.07 and a beta of 0.41. The company’s fifty day moving average is $57.88 and its 200 day moving average is $56.73. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.92%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BMY shares. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Citigroup lifted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price objective for the company from $63.00 to $70.00 in a research report on Monday, December 16th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $57.67.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Charles Schwab Trust Co purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at $285,000. Thrive Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 4.1% during the first quarter. Thrive Wealth Management LLC now owns 5,875 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 232 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Bristol-Myers Squibb by 21.4% in the first quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,062 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 1,246 shares in the last quarter. Boltwood Capital Management boosted its stake in shares of Bristol-Myers Squibb by 11.5% in the first quarter. Boltwood Capital Management now owns 5,245 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 540 shares during the period. Finally, Gilman Hill Asset Management LLC raised its stake in Bristol-Myers Squibb by 1.4% during the 1st quarter. Gilman Hill Asset Management LLC now owns 221,311 shares of the biopharmaceutical company’s stock valued at $13,498,000 after purchasing an additional 3,074 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is owned by insiders.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio’s 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio’s 1st Congressional District. He declared candidacy for the 2026 election.

Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor’s Office of Faith-Based and Community Initiatives.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.